COVID-19 Continues to Disrupt Patient Care Among Specialty Physicians, Though There Are Early Signs That Recovery is on the Horizon
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing multiple challenges with re-opening EXTON, Pa., July 6, 2020 / PRNewswire / – Results from the seventh wave of an ongoing study examining the impact of COVID-19 on specialty physician practices were released last week […]
Eli Lilly’s Reyvow Struggles to Gain Ground in the Acute Segment of the US Migraine Market, Overshadowed by AbbVie’s Ubrelvy and Biohaven’s Nurtec ODT, According to Spherix Global Insights
Lilly could build upon their existing payer relationships to construct favorable migraine portfolio contracting and position Reyvow as the preferred acute treatment for patients concurrently treated with calcitonin gene-related peptide monoclonal antibodies – a growing segment of the population EXTON, Pa., June 30, 2020 /PRNewswire/ — The number of companies active in the migraine space […]
Bristol Myers Squibb’s Zeposia and Janssen’s Ponesimod Could Be Early-Line Winners, While Biogen’s Vumerity Appears Relegated to Tolerability Switches Within the Fumarate Class
Current competition among the high-efficacy oral and monoclonal antibody therapies has done little to thwart growth of Genentech’s Ocrevus, but Novartis’ ofatumumab may have what it takes, according to Spherix Global Insights EXTON, Pa., June 16, 2020 /PRNewswire/ —Neurologist-reported treatment patterns in multiple sclerosis (MS) reveal a continued trend of using more high-efficacy disease-modifying therapies […]
Profiling Physicians Prescribing Concurrent Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody and OnabotulinumtoxinA for Migraine Prevention: Results from an Annual US Patient Chart Audit
Authors: Robert P. Cowan, MD, FAAN; Kristen Henn, MHSc; Jennifer Robinson; Virginia R. Schobel, MSc BACKGROUND: The use of combination therapy for the preventive treatment of migraine is common. In 2018, the anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) were introduced in the US, beginning with erenumab-aooe in May, fremanezumab-vfrm in September, and galcanezumab-gnlm in […]
Trending the First Two Years of Anti-Calcitonin Gene-Related Peptide Class Availability for Migraine Prevention: Results from an Independent Quarterly US Survey of Neurologists and Migraine Specialists
Authors: Virginia R. Schobel, MSc; Kristen Henn, MHSc; Jennifer Robinson BACKGROUND: Multiple anti-calcitonin gene-related peptide (CGRP) therapies have recently been approved for the prevention of episodic and chronic migraine, including erenumab-aooe (available since May 2018), fremanezumab-vfrm (September 2018), and galcanezumab-gnlm (October 2018). Approved in February 2020, eptinezumab introduced a fourth preventive therapy to the anti-CGRP […]
Newest Oral DMTs Haven’t Yet Made a Big Impact in the MS World
From: MDedge Neurology By: Bruce Jancin The three oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) approved last year in the United States haven’t made a big splash in the marketplace. So far, it’s more like a ripple, according to a study of neurologists’ prescribing patterns. “The recently approved therapies will initially be niched as […]
Specialty Physicians Report Signs of Rebound from COVID-19, but Are Pessimistic About Reopening Without a Resurgence
According to feedback from the sixth wave of COVID-19 impact tracking, Spherix Global Insights finds that patient volumes remain severely depressed and physicians are worried about patients with non-COVID conditions being able to access care EXTON, Pa., May 27, 2020 / PRNewswire / – Since the end of March, Spherix Global Insights has been tracking […]
Amid the COVID-19 Pandemic, Neurologists in Canada Report Pulling Back from EMD Serono’s Mavenclad and Sanofi Genzyme’s Lemtrada, While Roche’s Ocrevus Stalls, According to Spherix Global Insights
Use in treatment-naïve patients drives recent growth of Biogen’s Tecfidera and Genzyme’s Aubagio in Canada, as reported switch share has remained flat over the past year – reflecting the continued shift in using established oral agents earlier in the multiple sclerosis treatment algorithm EXTON, Pa., May 27, 2020 /PRNewswire/ — The COVID-19 pandemic has (at […]
Switching Patterns Among Relapsing-Remitting Multiple Sclerosis: Genentech’s Ocrevus on the Rise, Biogen’s Tecfidera Declines, and Teva’s Copaxone Remains Strong, According to Spherix Global Insights
Is there trouble in paradise for Genentech? US neurologist reevaluation of Ocrevus in PPMS patients, along with competitive pressure from Bristol Myers Squibb’s Zeposia, Novartis’ ofatumumab, and Janssen’s ponesimod, will further test the resiliency of the current leaders in the switch segment EXTON, Pa., April 30, 2020/PRNewswire/ — Genentech’s Ocrevus, Teva’s Copaxone, and Biogen’s Tecfidera […]
Changing Patterns in Disease-Modifying Therapy Selection for Treatment-Naive Multiple Sclerosis in the United States
Authors: Patricia K. Coyle, MD; Jennifer Robinson; Virginia R. Schobel. MSc OBJECTIVE: To evaluate changes in disease-modifying therapy (DMT) choice patterns for treatment-naive multiple sclerosis (MS) in the United States from 2016 to 2019. BACKGROUND: Cross-sectional patient-level data was collected once-yearly. It was then reviewed by an independent market intelligence agency which specializes in tracking […]
